Scott D L, Bracken P, Bacon P A, Husby G
Clin Sci (Lond). 1985 Mar;68(3):333-9. doi: 10.1042/cs0680333.
The clarification of turbid AA-amyloid-fibril-containing agarose gels by serum has been ascribed to degradation of the fibrils and designated as 'amyloid degrading factor'. In the present study, sera of 32 healthy blood donors and 32 patients with rheumatoid arthritis all showed 'degrading factor activity' against both AA amyloid fibrils and a non-fibrillar reticulin preparation of normal liver in an agarose plate assay. AL amyloid fibrils were not affected. The 'degrading activity' of serum was correlated with the serum albumin concentration, and the effect was also given by purified human and bovine serum albumin, although it was not seen with other serum proteins. The 'degrading activity' of serum against AA amyloid and reticulin was significantly correlated: both substrates showed low levels in a chronic disease such as rheumatoid arthritis, and reticulin inhibited 'degrading activity' against AA amyloid and vice versa. These results suggest the same process involves both substrates. 'Degrading activity' was also given by EDTA and a specific calcium chelator, and was inhibited by calcium and magnesium. An enzyme inhibitor showed only partial inhibition of the 'degrading activity' of serum, purified albumin, and EDTA. These results suggest that serum 'degrading factor activity' is a non-specific calcium-mediated effect against AA amyloid and reticulin preparations dispersed in agarose. It may represent a change in the degree of aggregation of these proteins rather than being an effect of proteolytic degradation. This confirms the conclusions of other workers that amyloid 'degrading factor activity' is an phenomenon in vitro of doubtful pathophysiological significance.
血清对含浑浊的AA淀粉样纤维的琼脂糖凝胶的澄清作用被归因于纤维的降解,并被命名为“淀粉样降解因子”。在本研究中,32名健康献血者和32名类风湿性关节炎患者的血清在琼脂糖平板试验中均显示出针对AA淀粉样纤维和正常肝脏的非纤维状网状纤维制剂的“降解因子活性”。AL淀粉样纤维未受影响。血清的“降解活性”与血清白蛋白浓度相关,纯化的人血清白蛋白和牛血清白蛋白也具有这种作用,尽管其他血清蛋白未显示出这种作用。血清对AA淀粉样蛋白和网状纤维的“降解活性”显著相关:在类风湿性关节炎等慢性疾病中,两种底物的水平都较低,网状纤维抑制对AA淀粉样蛋白的“降解活性”,反之亦然。这些结果表明相同的过程涉及两种底物。EDTA和一种特异性钙螯合剂也具有“降解活性”,且该活性受到钙和镁的抑制。一种酶抑制剂仅部分抑制血清、纯化白蛋白和EDTA的“降解活性”。这些结果表明,血清“降解因子活性”是一种针对分散在琼脂糖中的AA淀粉样蛋白和网状纤维制剂的非特异性钙介导效应。它可能代表这些蛋白质聚集程度的变化,而不是蛋白水解降解的作用。这证实了其他研究人员的结论,即淀粉样“降解因子活性”是一种体外现象,其病理生理意义存疑。